<DOC>
	<DOCNO>NCT01639248</DOCNO>
	<brief_summary>The purpose study determine activity ENMD-2076 define clinical benefit rate patient previously treat locally advanced metastatic triple negative breast cancer treat daily oral ENMD-2076 .</brief_summary>
	<brief_title>Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 Previously Treated Locally Advanced + Metastatic TNBC</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<criteria>1 . Patients must histologically cytologically diagnose locally advanced metastatic triplenegative breast cancer define negative estrogen receptor , progesterone receptor HER2 . 2 . Patients must measurable disease define revise RECIST criterion ( version 1.1 , Appendix C ) one lesion accurately measure one dimension within 4 week entry . Areas previous radiation may serve measurable disease . 3 . Prior treatment one three line systemic chemotherapy locally advance metastatic disease two week previous anticancer therapy include biologics recover expected toxicity ; least 4 week major surgery recover ; least 3 week radiation affect 25 % bone marrow recover ; 2 week palliative radiation recover . No 450 mg/m2 cumulative dose doxorubicin allow . 4 . Because dose adverse event data currently available use ENMD2076 patient &lt; 18 year age , child exclude study eligible future pediatric singleagent trial , applicable . 5 . ECOG performance status ≤ 1 ( Karnofsky ≥ 70 % ; see Appendix B ) . 6 . Patients must normal organ marrow function 7 . Patients must prestudy echocardiogram multigated acquisition ( MUGA ) scan actual leave ventricular ejection fraction great equal institution lower limit normal within one month prior start study . 8 . If maximum number nonbiopsy subject accrue study , willingness undergo 2 tumor biopsy . NOTE : Tumor biopsy may require , depend number subject agree undergo correlative study . 9 . Ability tolerate oral medication . 10 . Women child produce potential must agree use effective contraceptive method prior study entry , study participation , least 30 day last administration study medication . A serum pregnancy test within 72 hour prior initiation therapy require woman childbearing potential . 11 . Have ability understand requirement study , provide write informed consent include authorization release protect health information , abide study restriction , agree return require assessment . 12 . Availability archival tumor tissue ( core biopsy surgical tumor block ) analysis . Sites asked submit archival tissue ( subject may start study tissue available outside hospital , yet request receive ) . 1 . Women pregnant nursing . 2 . Have active , acute , chronic clinically significant infection bleed . 3 . Have uncontrolled hypertension ( systolic blood pressure great 150mmHg diastolic blood pressure great 100mmHg ) ; history congestive heart failure ( equal great Grade 2 ) . 4 . Have active angina pectoris , stroke recent myocardial infarction ( within 6 month ) . 5 . Have chronic atrial fibrillation QTc interval correct heart rate great 470 msec . 6 . Have additional uncontrolled serious medical psychiatric illness . 7 . Require therapeutic dos anticoagulant . 8 . CNS metastases . 9 . Have medical condition would impair administration oral agent include recurrent bowel obstruction , inflammatory bowel disease uncontrolled nausea , vomit diarrhea . 10 . Have persistent 2+ protein urinalysis ( patient 2+ proteinuria spot protein : creatinine ratio less 0.3 may enrol ) history nephrotic syndrome . 11 . Have additional malignancy diagnose within 5 year study enrollment exception basal squamous cell skin cancer cervical cancer situ . 12 . Patients may receive investigational agent . 13 . For patient undergo serial tumor biopsy , know bleed diathesis history abnormal bleeding require anticoagulation therapy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>